Clinical bottom line
Patient-reported outcomes (PROs) are increasingly recognized as vital components in oncology, providing insights into patients' perspectives on their health status, treatment experiences, and quality of life. Incorporating PROs into clinical decision-making can enhance patient-centered care, improve treatment adherence, and potentially lead to better clinical outcomes. However, the integration of PROs into routine practice remains variable, and further validation of their impact on treatment decisions is warranted.What the evidence shows
Recent studies have highlighted the importance of PROs in oncology. A systematic review by Basch et al. (2020) demonstrated that the use of PROs in clinical trials not only improves patient engagement but also provides valuable data that can inform treatment adjustments and enhance overall patient satisfaction (PMID: 32029874). The review emphasized that patients who reported their symptoms regularly experienced better symptom management and quality of life compared to those who did not.Moreover, a study by Dueck et al. (2017) found that routine collection of PROs in patients with advanced cancer led to significant improvements in overall survival and quality of life, suggesting that PROs can serve as a critical tool for monitoring treatment effectiveness and patient well-being (PMID: 28403439). This study supports the hypothesis that actively engaging patients in their care through PROs can lead to more tailored treatment approaches.
In addition, the National Comprehensive Cancer Network (NCCN) guidelines have begun to incorporate recommendations for the use of PROs in clinical practice, emphasizing their role in assessing treatment tolerability and patient satisfaction (NCCN Guidelines, 2021). These guidelines advocate for the systematic collection of PROs to inform treatment decisions and enhance patient-provider communication.
Caveats and uncertainty
While the evidence supporting the use of PROs is compelling, several caveats must be considered. The variability in PRO instruments, the lack of standardization in how PRO data is collected and interpreted, and potential biases in self-reported data can complicate the integration of PROs into clinical practice. Additionally, not all oncology practices have the resources or infrastructure to implement routine PRO collection effectively.Furthermore, while some studies indicate improved outcomes with PRO integration, the effect sizes can vary significantly across different cancer types and treatment regimens. More research is needed to determine the optimal methods for PRO implementation and to validate their impact on clinical outcomes across diverse patient populations.
How this may change practice
The integration of PROs into oncology practice has the potential to transform patient care by fostering a more patient-centered approach. By systematically collecting and analyzing PRO data, oncologists can gain deeper insights into the patient experience, allowing for more personalized treatment plans. This shift could lead to improved patient adherence to treatment, enhanced quality of life, and potentially better clinical outcomes.As oncology practices increasingly adopt electronic health records and digital health technologies, the feasibility of integrating PROs into routine care is likely to improve. Future developments in this area may include the use of mobile health applications to facilitate real-time PRO reporting, enabling timely interventions based on patient feedback.